Press Releases

April 10, 2024

Nuvation Bio Completes Acquisition of AnHeart Therapeutics

March 25, 2024

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

March 4, 2024

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

December 18, 2023

AnHeart Therapeutics and Innovent Announce China’s NMPA Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation

December 14, 2023

AnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 Inhibitor

November 22, 2023

AnHeart Therapeutics and Innovent Announce China’s NMPA Has Accepted a New Drug Application for Taletrectinib (ROS1 Inhibitor)

November 9, 2023

AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads

October 30, 2023

AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan

October 21, 2023

AnHeart Therapeutics’ Investigational Medicine Taletrectinib Shrank Tumors in More Than 90 Percent of People With ROS1-Positive Non-Small Cell Lung Cancer Who Were ROS1 TKI Naïve in Global Pivotal TRUST-II Trial 

September 28, 2023

AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer

September 7, 2023

AnHeart Therapeutics Announces Initiation of Global Phase 2 Trial Evaluating Safusidenib for IDH1-Mutant Glioma

April 3, 2023

AnHeart Therapeutics Appoints Edward Lang Jr. as Chief Business Officer

March 31, 2023

AnHeart Therapeutics Presents Updated Efficacy and Safety of Taletrectinib in Patients with ROS1-Positive Non–Small Cell Lung Cancer

March 13, 2023

AnHeart Therapeutics Announces Acceptance of Abstract for Oral Presentation at the European Lung Cancer Congress (ELCC) 2023

March 9, 2023

AnHeart Therapeutics Announces Publication of Taletrectinib Global Phase 2 Clinical Trial (TRUST-II) Design in Future Oncology

February 2, 2023

Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

December 15, 2022

AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma

October 19, 2022

AnHeart Therapeutics Expands US Team with Appointments in Clinical Research and Medical Affairs

September 12, 2022

AnHeart Therapeutics and NewG Lab Therapeutics Receive Orphan Drug Designation in Korea for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

August 4, 2022

AnHeart Therapeutics to Present Poster and Host Investigator Meeting at WCLC 2022 

August 3, 2022

AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer

August 1, 2022

AnHeart Therapeutics Appoints Dr. Shuanglian (Lian) Li as Chief Medical Officer (US)

June 6, 2022

AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022

June 1, 2022

AnHeart Therapeutics to Present at Upcoming Investor and Industry Conferences

March 21, 2022

AnHeart Therapeutics Announces Presentation at the European Lung Cancer Congress (ELCC) 2022

March 1, 2022

AnHeart Therapeutics and Innovent Biologics Receive NMPA Breakthrough Designation for Taletrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer

January 25, 2022

AnHeart Therapeutics Appoints Prof. Andrés Cervantes to Scientific Advisory Board